Table 2 Patients' clinical and analytical data by baseline group (BP: Blood pressure, Heart Rate (bpm); BMI Body Mass Index, Adominal circumference (cm); AST: Aspartate Aminotransferase; ALT: alanine aminotransferase; GGT: Gamma Glutamyl Transpeptidase CKD-EPI: Chronic Kidney Disease Epidemiology Collaboration)
From: Effectiveness of motivational interviewing in patients with dyslipidemia: a randomized cluster trial
VARIABLES | Experimental group n = 107 | Control group n = 120 | P value |
|---|---|---|---|
Systolic BP (mmHg): Mean ± SD | 129.26 ± 14.54 | 130.17 ± 15.67 | 0.595 |
Diastolic BP (mmHg): Mean ± SD | 79.04 ± 9.11 | 77.90 ± 9.49 | 0.228 |
Heart rate (bpm) (mmHg): Mean ± SD | 74.08 ± 10.06 | 74.18 ± 9.59 | 0.927 |
BMI: Mean ± SD | 28.47 ± 3.90 | 28.41 ± 4.47 | 0.670 |
Waist Circumference (cm): Mean ± SD | 94.47 ± 12.00 | 95.15 ± 11.51 | 0.744 |
Family history of early CVD: n (%) | 24 (22.4) | 16 (13.3) | 0.073 |
ECG: n (%) | 0.466 | ||
Normal | 95 (88.8) | 105 (87.5) | |
Alterations | 7 (6.5) | 5 (4.2) | |
Unknown | 5 (4.7) | 10 (8.3) | |
ANALYTICAL DATA: Mean ± SD | |||
Total Cholesterol (mg/dl) | 263.44 ± 28.26 | 259.26 ± 26.09 | 0.098 |
LDL Cholesterol (mg/dl) | 171.89 ± 27.28 | 171.10 ± 28.56 | 0.734 |
HDL Cholesterol (mg/dl) | 57.03 ± 17.63 | 55.55 ± 14.53 | 0.508 |
Triglycerides (mg/dl) | 170.64 ± 87.93 | 170.30 ± 106.05 | 0.516 |
Creatinine (mg/dl) | 0.83 ± 0.17 | 0.79 ± 0.19 | 0.039 |
Glucose (mg/dl) | 95.65 ± 10.68 | 95.76 ± 17.19 | 0.463 |
Uric Acid (mg/dl) | 4.86 ± 1.52 | 4.90 ± 1.56 | 0.883 |
GOT (UI/l) | 22.60 ± 7.96 | 24.26 ± 11.67 | 0.658 |
GPT (UI/l) | 25.65 ± 12.0 | 26.29 ± 16.90 | 0.693 |
GGT (UI/l) | 38.16 ± 35.47 | 36.14 ± 29.71 | 0.966 |
CKD-EPI (ml/min/1.73 m2) | 91.06 ± 12.92 | 92.98 ± 15.06 | 0.135 |
VASCULAR RISK: Mean ± SD | |||
SCORE (%) | 1.32 ± 1.50 | 1.54 ± 1.72 | 0.346 |
REGICOR (%) | 4.48 ± 2.61 | 4.47 ± 2.50 | 0.693 |
FRAMINGHAM (%) | 9.52 ± 6.05 | 9.98 ± 6.37 | 0.447 |